Table 2 Outcomes by molecular... | American Society of Hematology

Table 2

Outcomes by molecular characteristics and treatment

Outcome/treatment	FLT3/ITD status, %		NPM1 status, %		ITD/NPM1 status, %		CEBPA status, %		MN1 expression, %		Treatment
Outcome/treatment	WT	Mutant	WT	Mutant	NPM1 mutant, ITD WT	Others	WT	Mutant	Below median	Above median	Overall, %	HR/OR, 95% CI	P
CR												1.02 (0.79-1.32)	.9
ATRA	71	67	67	77	80	68	72	75	70	65	68
No ATRA	68	79	65	81	83	68	70	93	81	61	68
CR/CRi												1.16 (0.84-1.61)	.4
ATRA	84	84	81	89	89	82	84	90	79	82	CRi 15
No ATRA	86	89	85	89	94	84	85	93	91	83	CRi 16
RD												1.29 (0.84-1.98)	.2
ATRA	9	9	13	3	2	11	11	5	2	16	9
No ATRA	8	5	9	4	2	8	9	7	7	13	7
ID												1.02 (0.65-1.58)	.9
ATRA	7	7	7	8	9	6	6	5	19	4	8
No ATRA	6	7	7	6	4	7	6	0	2	2	8
30-day mortality
ATRA	6	5	5	7	8	6	4	5	15	4	7
No ATRA	6	7	5	6	4	6	5	0	5	2	7
8-week mortality
ATRA	9	7	8	8	9	8	7	5	17	6	9
No ATRA	8	8	9	7	4	9	8	7	5	5	10
8-year OS												0.98 (0.85-1.14)	.8
ATRA	35	31	27	47	56	28	38	35	44	44	33
No ATRA	34	31	30	39	40	32	33	47	36	30	30
8-year RFS												0.98 (0.83-1.14)	.8
ATRA	33	30	26	42	52	26	36	28	45	40	32
No ATRA	28	31	25	37	33	28	31	29	33	28	29
8-year CIR												0.93 (0.78-1.11)	.4
ATRA	50	53	54	46	37	55	48	61	38	49	51
No ATRA	59	52	61	49	51	59	53	64	54	53	56
8-year CIDCR												1.16 (0.82-1.63)	.4
ATRA	17	17	20	12	10	19	16	11	17	11	16
No ATRA	13	17	14	14	16	13	16	7	14	19	14

Outcome/treatment	FLT3/ITD status, %		NPM1 status, %		ITD/NPM1 status, %		CEBPA status, %		MN1 expression, %		Treatment
Outcome/treatment	WT	Mutant	WT	Mutant	NPM1 mutant, ITD WT	Others	WT	Mutant	Below median	Above median	Overall, %	HR/OR, 95% CI	P
CR												1.02 (0.79-1.32)	.9
ATRA	71	67	67	77	80	68	72	75	70	65	68
No ATRA	68	79	65	81	83	68	70	93	81	61	68
CR/CRi												1.16 (0.84-1.61)	.4
ATRA	84	84	81	89	89	82	84	90	79	82	CRi 15
No ATRA	86	89	85	89	94	84	85	93	91	83	CRi 16
RD												1.29 (0.84-1.98)	.2
ATRA	9	9	13	3	2	11	11	5	2	16	9
No ATRA	8	5	9	4	2	8	9	7	7	13	7
ID												1.02 (0.65-1.58)	.9
ATRA	7	7	7	8	9	6	6	5	19	4	8
No ATRA	6	7	7	6	4	7	6	0	2	2	8
30-day mortality
ATRA	6	5	5	7	8	6	4	5	15	4	7
No ATRA	6	7	5	6	4	6	5	0	5	2	7
8-week mortality
ATRA	9	7	8	8	9	8	7	5	17	6	9
No ATRA	8	8	9	7	4	9	8	7	5	5	10
8-year OS												0.98 (0.85-1.14)	.8
ATRA	35	31	27	47	56	28	38	35	44	44	33
No ATRA	34	31	30	39	40	32	33	47	36	30	30
8-year RFS												0.98 (0.83-1.14)	.8
ATRA	33	30	26	42	52	26	36	28	45	40	32
No ATRA	28	31	25	37	33	28	31	29	33	28	29
8-year CIR												0.93 (0.78-1.11)	.4
ATRA	50	53	54	46	37	55	48	61	38	49	51
No ATRA	59	52	61	49	51	59	53	64	54	53	56
8-year CIDCR												1.16 (0.82-1.63)	.4
ATRA	17	17	20	12	10	19	16	11	17	11	16
No ATRA	13	17	14	14	16	13	16	7	14	19	14

CRi indicates complete remission with incomplete count recovery; RD, resistant disease; ID, induction death; RFS, relapse-free survival; CIR, cumulative incidence of relapse; and CIDCR, cumulative incidence of death in CR/CR.

View Large

This Feature Is Available To Subscribers Only